Gil joined InterWest in 1996. As Managing Partner of the firm and the leader of InterWest’s Healthcare investment team, he invests in a broad array of healthcare opportunities, with a special interest in ophthalmology, digital health, and AI/robotics. Gil pioneered InterWest’s highly successful ophthalmology franchise. He was an early investor in Avedro, Glaukos, LenSx, and IntraLase, all category-creating ophthalmic companies that became standard-of-care for eye surgery around the world.
As a successful digital health investor, Gil built this important franchise for InterWest over the last twenty years through multiple companies. He was the founding institutional investor in Doximity, helping to build it into the leading digital network for physicians, engaging over 80% of U.S. doctors, with over one million users. Gil and InterWest supported Doximity’s June 2021 blockbuster IPO, which subsequently generated the largest investment return in InterWest’s history. Prior to that, he led the Series A of Epocrates, the first mobile application for physicians, serving on the board through its 2011 IPO and continuing as an investor through the 2013 acquisition by athenahealth.
He is a board member of Doximity (NYSE: DOCS), Glaukos (NYSE: GKOS), and a former board member and lead investor in Avedro (NASDAQ: AVDR, acquired by Glaukos), Epocrates (NASDAQ: EPOC, acquired by athenahealth), LenSx Lasers (acquired by Alcon), IntraLase (NASDAQ: ILSE, acquired by AMO), Neuronetics (NASDAQ: STIM), Restoration Robotics (NASDAQ: VERO, acquired by Venus Concept), and GoCheck.
Gil also serves as an independent board member of STAAR Surgical (NASDAQ: STAA), a leading ophthalmology company commercializing the EVO implantable contact lens for nearsightedness, and Orbis International, a global not-for-profit organization focused on preventing blindness. He is also a co-founder and program director of Eyecelerator, a first-of-kind ophthalmology innovation conference supported by a joint venture of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Its mission is to spur innovation in the ophthalmology sector by connecting scientific talent and entrepreneurs advancing eye care with mission-driven investors and business partners who can support go-to-market success. Previously, he helped to launch the Ophthalmology Innovation Summit (OIS), an ophthalmology business conference where he was an advisor and founding co-chairman from 2009 to 2019.
A former practicing eye surgeon, Gil completed an ophthalmology residency at Wills Eye Hospital and a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation fellow. He has a BA from Harvard University, an MD from the University of Pennsylvania and an MBA from Stanford University.
What is Gilbert H. Kliman's net worth?
The estimated net worth of Gilbert H. Kliman is at least $762,438.00 as of March 7th, 2024. Mr. Kliman owns 30,620 shares of Doximity stock worth more than $762,438 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Kliman may own. Learn More about Gilbert H. Kliman's net worth.
How do I contact Gilbert H. Kliman?
Has Gilbert H. Kliman been buying or selling shares of Doximity?
Gilbert H. Kliman has not been actively trading shares of Doximity during the last quarter. Most recently, Gilbert H. Kliman sold 826 shares of the business's stock in a transaction on Friday, February 25th. The shares were sold at an average price of $59.00, for a transaction totalling $48,734.00. Learn More on Gilbert H. Kliman's trading history.
Who are Doximity's active insiders?
Are insiders buying or selling shares of Doximity?
In the last twelve months, insiders at the sold shares 8 times. They sold a total of 34,214 shares worth more than $1,078,131.44. The most recent insider tranaction occured on April, 1st when Director Kira Scherer Wampler sold 2,500 shares worth more than $67,425.00. Insiders at Doximity own 39.4% of the company.
Learn More about insider trades at Doximity. Information on this page was last updated on 4/1/2024.
